202 related articles for article (PubMed ID: 15028469)
1. Biochemical remission after resection of prostate cancer lung metastasis.
Chao DH; Higgins JP; Brooks JD
Urology; 2004 Mar; 63(3):584-5. PubMed ID: 15028469
[TBL] [Abstract][Full Text] [Related]
2. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
3. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
5. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
[TBL] [Abstract][Full Text] [Related]
6. False elevations in prostate-specific antigen levels affecting patient management.
Kummar S; Shafi NQ
Clin Adv Hematol Oncol; 2004 Sep; 2(9):599-601; discussion 602. PubMed ID: 16163243
[No Abstract] [Full Text] [Related]
7. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
8. Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables.
Ferrari MK; McNeal JE; Malhotra SM; Brooks JD
Urology; 2004 Oct; 64(4):749-53. PubMed ID: 15491714
[TBL] [Abstract][Full Text] [Related]
9. The surgical learning curve for prostate cancer control after radical prostatectomy.
Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
[TBL] [Abstract][Full Text] [Related]
10. Avoidance and management of positive surgical margins before, during and after radical prostatectomy.
Bott SR; Kirby RS
Prostate Cancer Prostatic Dis; 2002; 5(4):252-63. PubMed ID: 12627209
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
[TBL] [Abstract][Full Text] [Related]
12. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
13. Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy?
Raj GV; Brashears JH; Anand A; Paulson DF; Polascik TJ
Urology; 2005 Feb; 65(2):332-6. PubMed ID: 15708048
[TBL] [Abstract][Full Text] [Related]
14. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus.
Levinson A; Nagler EA; Lowe FC
Urology; 2005 Jan; 65(1):91-4. PubMed ID: 15667871
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
18. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
19. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]